DE602005012155D1 - Arzneimittelabgabesysteme auf lipidbasis mit unnatürlichen phospholipase-a2-abbaubaren lipid-derivaten und ihre therapeutische verwendung - Google Patents
Arzneimittelabgabesysteme auf lipidbasis mit unnatürlichen phospholipase-a2-abbaubaren lipid-derivaten und ihre therapeutische verwendungInfo
- Publication number
- DE602005012155D1 DE602005012155D1 DE602005012155T DE602005012155T DE602005012155D1 DE 602005012155 D1 DE602005012155 D1 DE 602005012155D1 DE 602005012155 T DE602005012155 T DE 602005012155T DE 602005012155 T DE602005012155 T DE 602005012155T DE 602005012155 D1 DE602005012155 D1 DE 602005012155D1
- Authority
- DE
- Germany
- Prior art keywords
- lipid
- phospholipase
- based drug
- present
- unsaturative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000002632 lipids Chemical class 0.000 title abstract 5
- 102100037611 Lysophospholipase Human genes 0.000 title abstract 2
- 108010058864 Phospholipases A2 Proteins 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000012377 drug delivery Methods 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229930186217 Glycolipid Natural products 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940088679 drug related substance Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200401690 | 2004-11-03 | ||
| PCT/DK2005/000700 WO2006048017A1 (en) | 2004-11-03 | 2005-11-03 | Lipid-based drug delivery systems containing unnatural phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602005012155D1 true DE602005012155D1 (de) | 2009-02-12 |
Family
ID=36011931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602005012155T Expired - Fee Related DE602005012155D1 (de) | 2004-11-03 | 2005-11-03 | Arzneimittelabgabesysteme auf lipidbasis mit unnatürlichen phospholipase-a2-abbaubaren lipid-derivaten und ihre therapeutische verwendung |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080014253A1 (de) |
| EP (1) | EP1838283B1 (de) |
| JP (1) | JP2008518886A (de) |
| AT (1) | ATE418966T1 (de) |
| DE (1) | DE602005012155D1 (de) |
| WO (1) | WO2006048017A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE048419T2 (hu) | 2004-12-22 | 2020-08-28 | Nitto Denko Corp | Gyógyszerhordozó és kit gyógyszerhordozó kit fibrózis gátlására |
| US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
| JP5342834B2 (ja) * | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
| US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
| TWI407971B (zh) | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
| WO2009104649A1 (ja) * | 2008-02-22 | 2009-08-27 | 片山化学工業株式会社 | 合成糖脂質含有リポソーム |
| EP2123258A1 (de) | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomen zur Arzneimittelverabreichung |
| US8824305B2 (en) * | 2008-07-09 | 2014-09-02 | Qualcomm Incorporated | Paging schemes for local network access |
| US20100136647A1 (en) * | 2008-11-25 | 2010-06-03 | Ge Healthcare Bio-Sciences Ab | Method for production of cell attachment and culture surfaces |
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| DK177529B1 (en) | 2009-10-23 | 2013-09-08 | Bio Bedst Aps | Liposomes with improved storage stability |
| JP2014503582A (ja) * | 2011-01-28 | 2014-02-13 | コーニンクレッカ フィリップス エヌ ヴェ | 親水性プロドラッグの局所放出用担体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4622392A (en) * | 1984-06-21 | 1986-11-11 | Health Research Inc. (Roswell Park Division) | Thiophospholipid conjugates of antitumor agents |
| WO1988006439A2 (en) * | 1987-02-24 | 1988-09-07 | Regents Of The University Of Minnesota | Phospholipase a2-resistant liposomes |
| US5043164A (en) * | 1989-01-17 | 1991-08-27 | The University Of Tennessee Research Corporation | Blood-stable, cholesterol-free liposomes |
| US6413949B1 (en) * | 1995-06-07 | 2002-07-02 | D-Pharm, Ltd. | Prodrugs with enhanced penetration into cells |
| US5484911A (en) * | 1993-04-01 | 1996-01-16 | Health Research, Inc. | Nucleoside 5'-diphosphate conjugates of ether lipids |
| US6229002B1 (en) * | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
| US7517858B1 (en) * | 1995-06-07 | 2009-04-14 | The Regents Of The University Of California | Prodrugs of pharmaceuticals with improved bioavailability |
| US5827836A (en) * | 1996-11-15 | 1998-10-27 | Clarion Pharmaceuticals Inc. | Retinoid glycerol phospholipid conjugates |
| US6090407A (en) * | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
| EP1254143B1 (de) * | 2000-02-10 | 2004-09-29 | Liplasome Pharma A/S | Auf lipiden basierende systeme zur arzneistoffabgabe |
-
2005
- 2005-11-03 AT AT05799128T patent/ATE418966T1/de not_active IP Right Cessation
- 2005-11-03 US US11/665,159 patent/US20080014253A1/en not_active Abandoned
- 2005-11-03 JP JP2007538271A patent/JP2008518886A/ja not_active Withdrawn
- 2005-11-03 EP EP05799128A patent/EP1838283B1/de not_active Not-in-force
- 2005-11-03 WO PCT/DK2005/000700 patent/WO2006048017A1/en active Application Filing
- 2005-11-03 DE DE602005012155T patent/DE602005012155D1/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1838283A2 (de) | 2007-10-03 |
| WO2006048017A8 (en) | 2007-08-02 |
| WO2006048017A1 (en) | 2006-05-11 |
| JP2008518886A (ja) | 2008-06-05 |
| US20080014253A1 (en) | 2008-01-17 |
| EP1838283B1 (de) | 2008-12-31 |
| ATE418966T1 (de) | 2009-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005012155D1 (de) | Arzneimittelabgabesysteme auf lipidbasis mit unnatürlichen phospholipase-a2-abbaubaren lipid-derivaten und ihre therapeutische verwendung | |
| Irby et al. | Lipid–drug conjugate for enhancing drug delivery | |
| Lokeshwar et al. | Targeting hyaluronic acid family for cancer chemoprevention and therapy | |
| Quan et al. | Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes | |
| AR025444A1 (es) | Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos | |
| ES2875824T3 (es) | Composiciones de solución sólida y su uso en la inflamación crónica | |
| Ayral-Kaloustian et al. | Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin− rapamycin conjugates | |
| Wang et al. | The bone, the joints and the Balm of Gilead | |
| WO2001058910A3 (en) | Lipid-based drug delivery systems | |
| CN104955818B (zh) | 核苷激酶旁路组合物和方法 | |
| ES2552764T3 (es) | Métodos para el tratamiento de varias enfermedades y afecciones, y compuestos útiles para los mismos | |
| US10695432B2 (en) | Solid solution compositions and use in severe pain | |
| AR029175A1 (es) | Derivados 2-amino-fenilpurina, un proceso para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la preparacion de un medicamento | |
| JP2005518354A5 (de) | ||
| UY31405A1 (es) | "piperidino-dihidrotienopirimidas sustituidas" | |
| NZ605079A (en) | Biodegradable lipids for the delivery of active agents | |
| JP6280628B2 (ja) | 疼痛抑制用医薬組成物 | |
| IN2012DN00407A (de) | ||
| DK2319517T3 (da) | Anvendelse af prodrugs til okulær, intravenøs administration | |
| Cheng et al. | Site‐specific construction of long‐term drug depot for suppression of tumor recurrence | |
| US20220118091A1 (en) | Solid Solution Compositions and Use in Severe Pain | |
| Peng et al. | Discovery of an orally active and liver-targeted prodrug of 5-fluoro-2′-deoxyuridine for the treatment of hepatocellular carcinoma | |
| CA2522980A1 (en) | Water soluble wortmannin derivatives | |
| Zhong et al. | New Progress in Improving the Delivery Methods of Bisphosphonates in the Treatment of Bone Tumors | |
| CN112469411B (zh) | 供在由衰老细胞引起或介导的状况的临床管理中使用和用于治疗癌症的作为Bcl家族拮抗剂的氨基膦酸酯 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |